Justin Darrah, MD
Hematology & Oncology · West Hollywood, CANPI 1487947404
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,889 of the $4,587 with a category attached, or 84.8%. 7 manufacturers reported payments, led by Genmab U.S., Inc. at 50.7% of the total. Reporting peaked in 2024 at $2,326 and has fallen 96.3% since, to $87 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 12 payments — averaging $382.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genmab U.S., Inc.$2K
- Gilead$2K
- Jazz Pharmaceuticals Inc.$125
- AbbVie$101
- Pfizer$87
- Novartis$49
- plus $25 from 1 others
Across 342 payments — averaging $4769.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genmab A/s$971K
- Takeda Pharmaceuticals U.S.A., Inc.$544K
- Bristol Myers Squibb$96K
- Janssen Research & Development, LLC$20K
What the payments were for
- Consulting fees$3,88985%
- Travel & lodging$621%
- Food & beverage$63714%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genmab U.S., Inc. | 3 | $2,326 |
| Gilead | 3 | $1,875 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| AbbVie | 1 | $101 |
| Pfizer | 1 | $87 |
| Novartis | 2 | $49 |
| AstraZeneca | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,587 in reported general payments places this provider in the 50th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 20 | $269,133 |
| JakafiRuxolitinib Phosphate | 14 | $163,966 |
| ImbruvicaIbrutinib | 11 | $130,752 |
| ValacyclovirValacyclovir Hcl | 73 | $4,826 |
| Acyclovir | 120 | $3,543 |
| Entecavir | 16 | $2,560 |
| Ondansetron Hcl | 44 | $634 |
| Pantoprazole Sodium | 26 | $236 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 79 | $193 |
| Gabapentin | 18 | $166 |
| Prednisone | 32 | $115 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in West Hollywood
- Robert VescioWest Hollywood$1.1M
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.